Around two-thirds of all breast cancers have oestrogen receptor-positive (ER ) tumours. While adjuvant endocrine therapies have remained the standard treatment for ER breast cancer for the last few decades, a wide variety of effective, novel therapeutic options have emerged that are rapidly altering patient care. Experts from Europe discussed ...